ArticleCirculation reports2026
Incidence and Predictors of New-Onset Heart Failure After Catheter Ablation for Atrial Fibrillation in Patients With a Preserved Ejection Fraction.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence and predictors of new-onset heart failure (HF) after catheter ablation for atrial fibrillation (AF) remain unclear, particularly in patients with preserved left ventricular ejection fraction (EF ≥50%) and no prior HF. Methods and Results: We retrospectively analyzed 480 consecutive patients with EF ≥50% and no prior HF who underwent initial AF ablation. Recurrent atrial tachyarrhythmias (ATs) and new-onset HF were assessed during follow up. Landmark analyses at 3 and 12 months after the first procedure were performed to evaluate predictors of new-onset HF and the association between recurrence of early ATs and subsequent HF. Additionally, recurrence of ATs after the final ablation was examined as a time-dependent covariate using a Cox proportional hazards model. During a median follow up of 70 months (interquartile range 60-84 months), 18 (3.75%) patients developed new-onset HF. Age >75 years was the only consistent independent predictor in both landmark analyses. Early recurrence of ATs within 3 or 12 months was not associated with HF development. However, recurrence of ATs after the final procedure was independently associated with new-onset HF in a time-dependent analysis (hazard ratio 4.028; 95% confidence interval 1.564-10.378; P=0.004). Conclusions: In patients with preserved EF and no prior HF, new-onset HF after AF ablation was uncommon but clinically relevant. Durable rhythm control may be important to reduce HF risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.